At the movement Biostage, Inc. (NASDAQ:BSTG) is under coverage by number of analysts. 1 analyst given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 3.00 on scale of 1-5. Analysts mean target price for Biostage, Inc. (NASDAQ:BSTG) is $3.00 while their mean recommendation is 3.00 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved up 9.56% to end the day at $0.34. The current share price indicate that stock is -88.09% away from its one year high and is moving 16.41% ahead of its 52-week low.
Biostage, Inc. (NASDAQ:BSTG) announced the closing of its previously announced public offering of 20,000,000 shares of common stock and warrants to purchase 20,000,000 shares of common stock, for total gross proceeds of $8.0 million. The offering was priced at $0.40 per share of common stock, with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of $0.40 per share. Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as exclusive placement agent for the offering.
On 16 February 2017, Och-Ziff Capital Management Group LLC (NYSE:OZM) shares moved to $2.91 after starting the day at $3.20. Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 1 analyst of Thomson Reuters, 6 analysts given HOLD rating to the stock. Analyst’s mean target price for OZM is $3.43 while analysts mean recommendation is 2.90.
Och-Ziff Capital Management Group LLC (NYSE:OZM) one of the world’s biggest hedge fund firms, suffered withdrawals of about $13 billion over the last 13 months as the company settled a five-year bribery probe and saw its founder Dan Och singled out by regulators for ignoring red flags and corruption risks. Clients pulled about $8 billion in 2016 and an additional $4.8 billion in January through Feb. 1, with redemptions concentrated in the multistrategy funds, the company said Wednesday in a statement. Some of the asset declines were offset with performance gains, including a 3.8 percent return for its biggest multistrategy fund last year. Assets under management for the firm decreased to $33.6 billion as of Feb. 1 from $43.7 billion a year earlier. “We have come through a challenging year,” Och said Wednesday on a conference call. “The investigation and resulting settlement obviously had an impact on outflows, but we believe the worst quarter is behind us. That is not to say we won’t experience additional outflows, however, the tone of investor conversations over the past few months has changed for the better. Investors are pleased with our recent performance and to have the investigation behind us.”